An interventional study of Time Restricted Eating in Obesity, Morbid, Time Restricted Eating and Pregnancy Weight Gain, sponsored by University of Illinois at Chicago. Active, not recruiting at 1 site in United States. Open to female participants aged 18 Years to 44 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-14.
Sponsored by University of Illinois at Chicago · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 213 studies in Obesity, Morbid with a site in United States — 28 open to participants now, 36 under way, 1 of them phase 3. Obesity, Morbid · United States.
Among the 213 studies in Obesity, Morbid with a site in United States, this one is the 58th largest by planned enrollment of the 150 interventional ones that give a count, is one of 12 that started in 2024, is one of 107 with no phase, reaches primary completion later than 9 of the 34 other live ones, and was the 204th registered.
941 studies on the registry are indexed under Obesity, Morbid; 162 are open to participants now.
Browse Obesity, Morbid studies →28 of the 213 studies in Obesity, Morbid with a site in United States are open now. Recruiting first, the newest first:
Christopher C. Thompson, MD, MSc · Sites in United States
Ages 18–90
The Cleveland Clinic · Sites in United States
Ages 18–70
University of Maryland, Baltimore · Sites in United States
Ages 18+ · Women only
University of Missouri-Columbia · Sites in United States
Ages 18+
Salvador Navarrete · Sites in United States
Ages 18–70
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 109 Obesity, Morbid studies recruiting now, 21 (19%) set no upper age limit and 83 (76%) stop at 75 or younger; 8 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 44 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
213 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 11 · Phase 3 8 · Phase 4 13
First in 1980; this study’s year is marked. 12 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is close to the median of 62 across 601 interventional studies indexed under Obesity, Morbid.
Median enrollment 39 across the 150 interventional studies, 50 across the 63 observational. Of the 147 that completed or were terminated, 56 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 213 have an industry lead sponsor. The 10 most frequent:
University of Illinois at Chicago is the lead sponsor of 496 studies on the registry; 115 are open to participants now.
Of its 32 completed or terminated interventional studies of FDA-regulated products, 19 (59%) have results posted.
University of Illinois at Chicago has 2 studies filed under Obesity, Morbid — fewer than ten, so there is no comparison to draw.
8 of the studies in Obesity, Morbid with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06199154University of Maryland, BaltimoreInduction of Labor in Morbidly Obese Patients | 2026-12 |
| NCT05711758Christopher C. Thompson, MD, MScEfficacy and Safety of Endoscopic Antral Myotomy as a Novel Weight Loss Procedure | 2026-12 |
| NCT02602769Columbia UniversityWhole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome | 2026-12 |
| NCT05215886University of California, DavisCognitive Impairment, Obesity, and the Effects of Bariatric Surgery | 2026-12-31 |
| NCT03868592Mayo ClinicLong-term, Substantial Weight Loss and Insulin Regulation of Lipolysis | 2027-05 |
Add all 8 to your calendar (.ics) → With an account.
Among the 213 studies in Obesity, Morbid with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
In the United States, a body mass index (BMI) of at least 35.0 kg/m2 affects about 15% of women of reproductive age. Severe obesity is a significant predictor of adverse perinatal outcomes including gestational diabetes mellitus, pre-eclampsia, premature birth, and at its most severe, fetal death, birth defects and a three-fold greater risk of maternal mortality. Observational studies suggest weight maintenance and even modest body fat loss and altering the maternal metabolic milieu (availability of glucose and lipids) in the gestational period may be important to reducing perinatal health risks among pregnant females with severe obesity. The proposed research aims to assess time-restricted eating in the 2nd and 3rd trimesters of pregnancy to explore the effects on maternal weight, and perinatal health outcomes compared to standard clinical care.
Severe obesity is a contributor to adverse perinatal outcomes. The prevalence of severe obesity is on the rise in the United States (U.S.), having increased from 6.4% of the adult population in 2011-2012 to just over 9% of adults in 2017-2018. The prevalence of severe obesity among reproductive age females is approximately 10%. This is an alarming statistic given severe obesity is a predictor of adverse perinatal outcomes including gestational diabetes mellitus, preeclampsia, premature birth (both spontaneous and medically indicated), and at its most severe, fetal death, birth defects, and a three-fold greater risk of maternal mortality. Observational studies suggest weight maintenance and even modest body fat loss and altering the maternal metabolic milieu (availability of glucose and lipids) in the gestational period may be important to reducing perinatal health risks among pregnant females with severe obesity. Existing lifestyle interventions (calorie control/dietary pattern changes/physical activity) have showed modest effects on attenuating excess gestational weight gain and modest effects on perinatal health outcomes among pregnant females with obesity. Time- restricted eating, where an individual simply watches the clock and consumes calories within a particular eating window, is a simple and highly accessible eating pattern that has the potential to minimize gestational weight gain, reduce excess glucose and lipids, and improve metabolic health among pregnant females with severe obesity all of which could translate to improved perinatal health outcomes. Yet there are no clinical trials of time-restricted eating in pregnancy. The investigators aim to test the safety, feasibility, and acceptability of time-restricted eating among 60 pregnant females with severe obesity. The investigators will examine time-restricted eating safety, feasibility and acceptability (8-hr eating window in the 2nd trimester \& 10-hr eating window in the 3rd trimester), and explore its effects on weight, cardiometabolic risk markers and perinatal health outcomes vs. Standard Care. The intervention will begin between 14 - \< = 20 weeks gestational age and continue through admission for labor and delivery. The study will involve weekly meetings with a nutritionist, and research visits at baseline (\~17 weeks gestational age), 27-29 weeks gestational age and 35-37 weeks gestational age as well as monthly check-ins for maternal and fetal health monitoring. Maternal and neonatal data from labor and delivery will also be collected from electronic health records. Glucose will be continuously monitored for 10 days at 20 weeks gestational age and 34 weeks gestational age (optional). The goal of our work is to reduce and prevent adverse perinatal outcomes among pregnant females with severe obesity. Given the relative simplicity of time-restricted eating it can be easily disseminated in clinic demonstrating its strong potential for wide-scale public health impact.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants randomized to the time-restricted eating arm will be instructed to eat ad libitum during an 8-hr window daily 11am - 7pm in the 2nd trimester and 10-hr eating window from 10am - 8pm in the 3rd trimester and abstain from caloric foods and beverages for the remaining 14-16 hours. During the eating window there will be no restrictions on types or quantities of foods consumed. Moreover, participants will not be required to monitor calorie intake during the ad libitum eating period. During the fasting period, participants will be encouraged to drink plenty of water and will be allowed to consume calorie-free beverages.
Behavioral: Time Restricted Eating
The standard care arm will not receive diet-related counseling. Participants will meet with study staff weekly to record health changes and to transmit weight through the text messaging platform. The remote videoconferencing visits will occur at the same day and time each week. Standard care participants will attend the in-person research data collection visits. Participants will be asked to maintain current (baseline) level of physical activity throughout the intervention.
The time-restricted eating arm will be instructed to eat ad libitum during an 8-hr window daily (10am - 6pm OR 11am - 7pm) in the 2nd trimester and 10-hr eating window from (9am - 7pm OR 10am - 8pm) in the 3rd trimester and abstain from caloric foods and beverages for the remaining 14-16 hours.
Recruitment Feasibility
≥ 30% of those approached enroll
Time frame: From 6 months through 32 months (the funding period is 36 months)
Trial safety - Maternal Complete Blood Count
% and n with abnormal results by study arm
Time frame: Baseline (14-20 weeks gestational age) and monthly through labor and delivery, about 6 months
Trial safety - Non-stress Test for Fetal Safety
Measured with a fetal monitor to examine baby's heart rate over time (usually 20 to 30 minutes, but sometimes up to an hour) % and n with abnormal results by study arm
Time frame: 29-31 weeks gestational age and 35-37 weeks gestational age
Intervention acceptability
Semi-structured interviews
Time frame: 25-27 weeks gestational age and 35-37 weeks gestational age
Research visit feasibility
Number of data collection visits completed with \>=80% completed at each timepoint and completeness of data
Time frame: Baseline, 25-27 weeks gestational age and 35-37 weeks gestational age
Intervention (TRE) session feasibility
Number and % of intervention sessions completed by TRE participants
Time frame: Weekly from baseline through labor and delivery, about 6 months
TRE adherence
Response rate to daily text message regarding eating start and stop time to determine adherence to the eating window goal is \>= 80% adherence on days reported
Time frame: Daily from enrollment to labor and delivery (TRE arm only), about 6 months
Trial safety - Maternal health checks
Weekly maternal health checks via videoconference in TRE and control group that is verified with electronic health record
Time frame: Weekly from baseline to labor and delivery, about 6 months, % and n for health events reported by study arm
Trial safety - Maternal outcomes
Data obtained from the participant's electronic health record (gestational age at delivery, gestational diabetes, gestational hypertension, preeclampsia, c-section, spontaneous pre-term birth, iron deficiency anemia) % and n with abnormal results by study arm
Time frame: Labor and delivery
Trial safety - Neonatal outcomes
Data obtained from the participant's electronic health record (small or large for gestational age, neonatal intensive care admission, jaundice, APGAR score) % and n with abnormal results by study arm
Time frame: Labor and delivery
Trial Retention
n and % of women retained through the final in-person data collection with \>= 80% retained
Time frame: 35-37 week gestational age
Maternal Body Weight
Body weight in kilograms
Time frame: Baseline (14-20 weeks), 25-27 weeks gestational age, 35-37 weeks gestational age
Maternal Fasting Blood Glucose
Measured in serum
Time frame: Baseline (14-20 weeks gestational age), 25-27 weeks gestational age, 35-37 weeks gestational age
Maternal Fasting Insulin
Measured in serum
Time frame: Baseline (14-20 weeks gestational age), 25-27 weeks gestational age, 35-37 weeks gestational age
Maternal Fasting Blood Lipids
Cholesterol and triglycerides
Time frame: Baseline (14-20 weeks gestational age), 25-27 weeks gestational age, 35-37 weeks gestational age
Maternal C-reactive protein
Measured in plasma
Time frame: Baseline (14-20 weeks gestational age), 25-27 weeks gestational age, 35-37 weeks gestational age
Maternal Systolic Blood Pressure
Measured with participant in a seated position using an automated cuff
Time frame: Baseline (14-20 weeks gestational age), 25-27 weeks gestational age, 35-37 weeks gestational age
Maternal Diastolic Blood Pressure
Measured with participant in a seated position using an automated cuff
Time frame: Baseline (14-20 weeks), 25-27 weeks gestational age, 35-37 weeks gestational age
Maternal Hb A1c
Measured from whole blood
Time frame: Baseline (14-20 weeks gestational age), 25-27 weeks gestational age, 35-37 weeks gestational age
Plan to share: No
No publications or documents are linked to this record.
Ran from Sep 2024 to primary completion in Sep 2026, 24 months.
Of 273 non-industry interventional studies with no phase under Obesity, Morbid, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 48. This study's 24 months is close to that.
Counting every sponsor, half of 285 studies reached it within 25 months; a quarter within 11 and three quarters within 48.
Primary completion moved once since we started tracking on Sep 25, 2026: Aug 2026 → Sep 2026, on Oct 14, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Illinois at Chicago →